Molecular pathology

Avero Diagnostics Expands COVID-19 Testing Capabilities with Launch of Serology Testing

Retrieved on: 
Tuesday, August 25, 2020
Health, Other Health, Medical specialties, Medicine, Zoonoses, Sarbecovirus, Branches of biology, COVID-19 testing, Coronavirus disease, Severe acute respiratory syndrome coronavirus 2, Anatomical pathology, Serology, Severe acute respiratory syndrome coronavirus, Molecular pathology

Avero Diagnostics , a physician-owned laboratory, is pleased to announce the expansion of its COVID-19 testing portfolio with the addition of the Roche Elecsys Anti-SARS-CoV-2 antibody test.

Key Points: 
  • Avero Diagnostics , a physician-owned laboratory, is pleased to announce the expansion of its COVID-19 testing portfolio with the addition of the Roche Elecsys Anti-SARS-CoV-2 antibody test.
  • As the medical and scientific communities work to understand and stop the spread of COVID-19, serological testing serves as a piece of the very complex puzzle, said Trae Mattison, MD, Managing Partner, Avero Diagnostics.
  • Avero Diagnostics CLIA-certified and CAP-accredited laboratory is using the Roche immunoassay for the qualitative detection of antibodies against SARS-CoV-2.
  • Avero Diagnostics vision is to lead the healthcare industry in the delivery of anatomic pathology, molecular pathology and genetic testing.

Acupath Launches COVID19 Testing in NY and Beyond

Retrieved on: 
Friday, May 29, 2020
Anatomical pathology, Pathology, Molecular pathology, Urology, Biology

PLAINVIEW, N.Y., May 29, 2020 /PRNewswire/ -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, announces the launch of COVID-19 testing utilizing the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit.

Key Points: 
  • PLAINVIEW, N.Y., May 29, 2020 /PRNewswire/ -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, announces the launch of COVID-19 testing utilizing the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit.
  • With results available within 24 48 hours, Acupath's test is highly sensitive, as it is one of the few labs targeting regions of three coronavirus genes; orf-1ab, S protein, and N protein, as well as MS2 phage control.
  • "Thanks to the hard work of our team, we are now able to do our part and expand testing capabilities in the greater New York City area and beyond to help the region and country reopen," said Steve Kamalic, Chief Operating Officer.
  • Founded in 1998 and based in Plainview, NY (Long Island), Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Women's Health, Otolaryngology, Podiatry, and Hematology / Oncology.

Avero Diagnostics Now Offering COVID-19 Testing

Retrieved on: 
Tuesday, May 19, 2020
Other Health, Research, General Health, Medical devices, Infectious diseases, Hospitals, Genetics, Science, Biotechnology, Nursing, Other Science, Health, Anatomical pathology, Molecular pathology, Pathology

Avero Diagnostics , a physician-owned laboratory, is now providing molecular testing for COVID-19.

Key Points: 
  • Avero Diagnostics , a physician-owned laboratory, is now providing molecular testing for COVID-19.
  • For the protection of our community, its imperative that testing be made available to people who are symptomatic or have been exposed to someone with COVID-19, said Trae Mattison, MD, Managing Partner, Avero Diagnostics.
  • Avero Diagnostics is working to coordinate with regional officials to ensure our lab is added to the official testing capacity for the region, support the demands of the local healthcare community, and help alleviate the current testing shortfall.
  • Avero Diagnostics vision is to lead the healthcare industry in the delivery of anatomic pathology, molecular pathology and genetic testing.

Largest North American Site for FSHD Muscular Dystrophy Testing Adopts Bionano Genomics’ Saphyr for Majority of Clinical Tests 

Retrieved on: 
Wednesday, April 22, 2020
Facioscapulohumeral muscular dystrophy, Muscular dystrophy, Natural sciences, Branches of biology, Biology, Laboratory techniques, Assay, Pathology, Molecular pathology

The UIHC recently completed development of an FSHD assay on Saphyr and validated its results by processing patient samples for FSHD.

Key Points: 
  • The UIHC recently completed development of an FSHD assay on Saphyr and validated its results by processing patient samples for FSHD.
  • Following this evaluation, the UIHC is implementing this month a Saphyr-based assay into its clinical testing workflow.
  • One component of genetically confirming a diagnosis of FSHD is measuring the exact number of D4Z4 repeats.
  • The Molecular Pathology Laboratory at the University of Iowa, directed by Aaron Bossler MD, PhD, is the largest FSHD testing site in North America and to date has relied on the labor-intensive technique of Southern blotting for FSHD molecular diagnostic testing.

Slone Partners Places Roger D. Klein, M.D., J.D., FCAP, as Chief Medical Officer at OmniSeq

Retrieved on: 
Tuesday, April 14, 2020
Anatomical pathology, Molecular pathology, Slone, Biology, Pathology, Precision medicine, Academic disciplines, Life sciences

SOUTH RIDING, Va., April 14, 2020 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences and diagnostics companies, has announced the placement of Roger D. Klein, M.D., J.D., FCAP, as Chief Medical Officer (CMO) of OmniSeq.

Key Points: 
  • SOUTH RIDING, Va., April 14, 2020 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences and diagnostics companies, has announced the placement of Roger D. Klein, M.D., J.D., FCAP, as Chief Medical Officer (CMO) of OmniSeq.
  • "Dr. Klein is a highly accomplished leader in the innovative fields of molecular pathology, oncology and precision medicine," said Slone Partners President Tara Kochis-Stach .
  • Dr. Klein joins OmniSeq with nearly 30-years of experience in the medical industry and a distinguished career in molecular pathology.
  • OmniSeq offers three NGS-based assays: OmniSeq MSI NGS, OmniSeq Advance, and OmniSeq Comprehensive.

Memphis-Based Poplar Healthcare Processing COVID-19 Tests

Retrieved on: 
Tuesday, March 31, 2020
Clinical Laboratory Improvement Amendments, Healthcare in the United States, Pathology, Emergency Use Authorization, Molecular pathology, Coronavirus, Biology, Health, Articles

MEMPHIS, Tenn., March 31, 2020 /PRNewswire-PRWeb/ -- Poplar Healthcare, a leading anatomic and molecular pathology laboratory headquartered in Memphis, TN, announced today that it is now processing COVID-19 tests in its 113,000-square-foot, high-complexity CLIA-certified and CAP-accredited laboratory in Memphis, Tennessee.

Key Points: 
  • MEMPHIS, Tenn., March 31, 2020 /PRNewswire-PRWeb/ -- Poplar Healthcare, a leading anatomic and molecular pathology laboratory headquartered in Memphis, TN, announced today that it is now processing COVID-19 tests in its 113,000-square-foot, high-complexity CLIA-certified and CAP-accredited laboratory in Memphis, Tennessee.
  • In addition, Poplar Healthcare is performing testing on the Roche cobas z480 analyzer and has submitted for Emergency Use Authorization (EUA) from the FDA.
  • "As coronavirus spreads across the nation at an alarming rate, Poplar Healthcare is well situated to help control the outbreak by providing patients and providers access to COVID-19 testing," stated Poplar Healthcare Medical Director, Shawn Kinsey, MD.
  • Poplar Healthcare is one of the largest physician-owned pathology group practices in the United States, offering a wide variety of DNA- and RNA-based molecular tests.

Association for Molecular Pathology Commends Senator Rand Paul for Introducing the Verified Innovative Testing in American Laboratories (VITAL) Act of 2020

Retrieved on: 
Wednesday, March 18, 2020
Branches of biology, Biology, Medicine, Biotechnology, Molecular diagnostics, Medical laboratory, Molecular pathology, Clinical Laboratory Improvement Amendments, Pathology, Draft:Association for Molecular Pathology

ROCKVILLE, Md., March 18, 2020 /PRNewswire/ -- The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, applauds US Senator Rand Paul (R-KY) for introducing new legislation to allow molecular pathology professionals to continue advancing and offering laboratory developed testing procedures (LDPs) for patient care.

Key Points: 
  • ROCKVILLE, Md., March 18, 2020 /PRNewswire/ -- The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, applauds US Senator Rand Paul (R-KY) for introducing new legislation to allow molecular pathology professionals to continue advancing and offering laboratory developed testing procedures (LDPs) for patient care.
  • The Verified Innovative Testing in American Laboratories (VITAL) Act of 2020 clarifies the federal regulatory authority over LDPs and encourages the modernization of the existing Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare and Medicaid Services (CMS).
  • "We are pleased that Senator Rand Paul introduced this legislation that will provide clinical laboratories with clarity and predictability in federal oversight of testing programs," said Karen E. Weck, MD, President of the Association for Molecular Pathology.
  • To view the full-text version of the VITAL Act of 2020, visit www.amp.org/VITAL
    The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics.

Association for Molecular Pathology Calls on Senate to Close Coverage Gaps for Clinical Laboratory Testing in Families First Coronavirus Response Act

Retrieved on: 
Monday, March 16, 2020
Biology, Branches of biology, Life sciences, Animal virology, Biotechnology, Molecular diagnostics, Coronavirus, Molecular pathology, Pathology

6201, the Families First Coronavirus Response Act, as passed by the House of Representatives on March 14, 2020.

Key Points: 
  • 6201, the Families First Coronavirus Response Act, as passed by the House of Representatives on March 14, 2020.
  • The following statement is attributable to Mary Steele Williams, Executive Director of the Association for Molecular Pathology.
  • 6201, the Families First Coronavirus Response Act, fails to provide adequate coverage for all patients.
  • The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics.

Hologic Places 1,000th Panther Molecular Diagnostics System in the United States

Retrieved on: 
Thursday, March 12, 2020
Infectious diseases, Biotechnology, Health, Medical devices, Biology, Branches of biology, Life sciences, Anatomical pathology, Hologic, Molecular diagnostics, Panther, Pathology, Molecular pathology, Gen-Probe, the Panther System, PathGroup, Hologic

Hologic (Nasdaq: HOLX) announced today the 1,000th placement of a Panther system, the Companys market-leading automated molecular instrument, in a United States diagnostics laboratory.

Key Points: 
  • Hologic (Nasdaq: HOLX) announced today the 1,000th placement of a Panther system, the Companys market-leading automated molecular instrument, in a United States diagnostics laboratory.
  • PathGroup installed its first Hologic Panther system in 2012, and continues to expand its infectious disease, cytology and molecular pathology services to clients and hospital systems.
  • The Panther molecular diagnostics system is a best-in-class, fully automated, sample-to-result platform with adaptable workflow options and a consolidated testing menu.
  • Hologic, Panther, Panther Fusion and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Asuragen to Present at 2019 Association for Molecular Pathology (AMP) Annual Meeting

Retrieved on: 
Wednesday, October 30, 2019
Biotechnology, Medical devices, Health, Genetics, Oncology, Biology, Life sciences, Branches of biology, Medical genetics, Biotechnology, Molecular diagnostics, Pathology, Asuragen, Molecular pathology

Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host three corporate workshops and present multiple scientific posters highlighting their rapidly expanding product portfolio and industry collaborations at the upcoming 2019 Association for Molecular Pathology (AMP) Annual Meeting & Expo November 7-9 in Baltimore.

Key Points: 
  • Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host three corporate workshops and present multiple scientific posters highlighting their rapidly expanding product portfolio and industry collaborations at the upcoming 2019 Association for Molecular Pathology (AMP) Annual Meeting & Expo November 7-9 in Baltimore.
  • Asuragen will present four posters during the Scientific Poster Sessions, demonstrating its continuing innovation in translating molecular biology to impactful diagnostic products.
  • Asuragens Corporate Workshops will occur in Room 338 of the Baltimore Convention Center at 10am, 12pm, and 2pm, on Wednesday, respectively.
  • Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology.